Hypothesis

Combined low‑dose piracetam, Bacopa monnieri, and selank will synergistically shorten P300 latency and improve working memory performance during acute psychosocial stress, an effect blocked if cortisol remains elevated.

Rationale

• Racetams boost adenylate kinase activity and glucose utilization under hypoxia, but their memory benefits are abolished by high corticosteroid levels [3].
• Bacopa monnieri enhances cholinergic transmission and provides antioxidant protection [4].
• Selank, a heptapeptide analog of tufsin, reduces anxiety‑induced cortisol release and modulates GABAergic tone, thereby lowering the inhibitory gate on racetam/cholinergic signaling.
• When adenylate kinase activity is upregulated (piracetam) and cellular redox state is improved (Bacopa), hippocampal LTP becomes more resistant to cortisol‑mediated suppression. Selank’s cortisol‑lowering action removes the block, allowing the two metabolic enhancers to produce a supra‑additive gain in neural efficiency, measurable as reduced P300 latency.

Predicted Outcomes

1. Electrophysiology: Participants receiving the triple stack will show a ≥15 % reduction in P300 latency relative to placebo during a working‑memory task, whereas single‑agent or dual‑agent conditions will produce ≤5 % changes.
2. Behavior: Accuracy on a 2‑back n‑back task will improve by ≥12 % in the triple stack condition under stress, with no significant change in placebo or monotherapy arms.
3. Biochemistry: Salivary cortisol will be ↓20 % in the triple stack group compared to stress‑only controls, correlating inversely with P300 latency shifts (r ≤ ‑0.4).

Experimental Design (Falsifiable)

• Design: Double‑blind, placebo‑controlled, 5‑arm crossover (placebo, piracetam alone, Bacopa alone, selank alone, triple stack). Each arm separated by a 7‑day washout.
• Participants: 60 healthy adults (aged 20‑35), stratified by baseline cortisol response to the Trier Social Stress Test (TSST).
• Procedures: After capsule ingestion (piracetam 800 mg, Bacopa 150 mg BID, selank 250 µg intranasal), participants undergo TSST, then complete an auditory oddball task (EEG recorded) followed by a 2‑back n‑back.
• Measures: P300 latency (FCz), n‑back accuracy, salivary cortisol pre‑ and post‑TSST, plasma adenylate kinase activity (optional subset).
• Analysis: Mixed‑effects model testing interaction (drug × stress) on P300 latency; a non‑significant interaction or effect size below the predefined threshold falsifies the synergy claim.

Falsifiability

If the triple stack fails to produce a statistically significant reduction in P300 latency (p > 0.05) or if cortisol reduction does not mediate the electrophysiological improvement (mediation analysis ns), the hypothesis is rejected. Conversely, a significant interaction meeting the predicted effect sizes would support the proposed mechanistic synergy.